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Abstract: The majority of diabetic patients with renal involvement are not biopsied. 
Studies evaluating histological findings in renal biopsies performed in diabetic patients 
have shown that approximately one third of the cases will show pure diabetic nephropathy, 
one third a non-diabetic condition and another third will show diabetic nephropathy with  
a superimposed disease. Early diagnosis of treatable non-diabetic diseases in diabetic 
patients is important to ameliorate renal prognosis. The publication of the International 
Consensus Document for the classification of type 1 and type 2 diabetes has provided 
common criteria for the classification of diabetic nephropathy and its utility to stratify risk 
for renal failure has already been demonstrated in different retrospective studies. The 
availability of new drugs with the potential to modify the natural history of diabetic 
nephropathy has raised the question whether renal biopsies may allow a better design of 
clinical trials aimed to delay the progression of chronic kidney disease in diabetic patients. 








Diabetes mellitus (DM) represents one of the most important health problems worldwide. Over the 
last years, the global prevalence of type 2 diabetes mellitus (T2DM) has reached epidemic proportions 
fuelled by the global rise in the prevalence of obesity and unhealthy lifestyles. The World Health 
Organization foresees an increase in the global prevalence of DM from 2.8% in year 2000 to 4.4% in 
year 2030. This estimation represents that there will be 366 million adults with diabetes in 2030 [1].  
In Spain, between 6% and 10% of the adult population suffers from DM and this percentage is as high 
as 12% in The Canary Islands [2]. Between 6.3% and 7.4% of the total budget of the Spanish National 
Health Service is spent in diabetes care, which represents an annual cost of 1.290 € to 1.476 € per 
patient [3]. 
Diabetes Mellitus is the fifth-leading cause of death worldwide and is associated with an increased 
risk of cardiovascular disease [4]. Chronic kidney disease (CKD) is a common complication in diabetic 
patients and further contributes to increased mortality and cardiovascular disease. The prevalence of 
CKD defined as an estimated glomerular filtration rate (e-GFR) <60 mL/min/1.73 m2 and/or the 
presence of microalbuminuria in adults with T2DM was 45% and raised to 61% in patients >65 years 
according to the NHANES report [5]. Furthermore, diabetic nephropathy is the most common cause of 
end-stage renal disease in Western Societies, accounting for approximately 45% of patients on renal 
replacement therapy. Moreover, patient survival in diabetics on maintenance dialysis is lower than in 
non-diabetic patients with end-stage renal disease due to other renal diseases [6]. 
2. Clinical Diagnosis of Diabetic Kidney Disease 
The first clinical sign suggesting renal involvement due to diabetes is hyperfiltration characterized 
by increased glomerular filtration rate over 120 mL/min/1.73 m2, which is followed by the onset of 
microalbuminuria (albumin excretion >30 mg/g creatinine). 
The natural history of the renal involvement in diabetes is better characterized in patients with type 
I diabetes mellitus (T1DM) since the beginning of diabetes is precisely known. It has been observed 
that microalbuminuria in patients with T1DM rarely appears within the first five years. Without 
specific intervention, 80% of type I diabetic patients that develop microalbuminuria will evolve to 
macroalbuminuria (albumin excretion >300 mg/g creatinine) at an average time of 10–15 years.  
During this period of time, hypertension will also appear. Once macroalbuminuria is present, the 
glomerular filtration rate decreases progressively at a variable rate, ranging between 2–20 mL/min/year. 
Approximately 50% of patients with T1DM and macroalbuminuria will progress to end stage renal 
disease in a period of 10 years and 75% in a period of 20 years [7]. 
The natural history of diabetic nephropathy is less well established in T2DM since alterations  
of glucose metabolism are indolent and the diagnosis of diabetes is usually established many years 
afterwards. A proportion of patients with T2DM already display micro or even macroalbuminuria  
at the time of diagnosis. Without specific intervention, 20% to 40% of patients with T2DM presenting 
microalbuminuria are going to progress to macroalbuminuria. However, 20 years after the beginning  
of macroalbuminuria, only 20% of patients will progress to end stage renal disease. In Figure 1, the 
natural history of diabetic nephropathy is summarized [7]. 




Figure 1. Natural history of diabetic nephropathy. There is a poor correlation between 
renal function deterioration, degree of albuminuria and histological findings. UAER: 
Urinary albumin excretion rate; CKD: chronic kidney disease; ESRS: end stage renal 
disease; * mg/gr creatinine; ** mL/mint/1.73 m2. 
Diabetic glomerulopathy is the characteristic lesion of patients with diabetic nephropathy. However, 
only a small proportion of diabetic patients are biopsied. Accordingly, the term diabetic kidney  
disease (DKD) is the preferred one to refer to patients in whom diabetic nephropathy is suspected on 
clinical grounds [8]. The term diabetic nephropathy should only be employed in diabetic patients with 
histological confirmation of renal involvement due to diabetes [9]. Thus, the term DKD represents  
a probability for the diagnosis of diabetic nephropathy and the presence of renal insufficiency and/or 
albuminuria in diabetic patients can be due to other renal diseases different from diabetic nephropathy. 
In a study reviewing 620 biopsies made in patients with diabetes in 2011, Sharma et al., showed that 
among 2642 native kidney biopsies, 37% of patients showed pure diabetic nephropathy, 36% showed a 
non-diabetic renal disease and in 27% of patients diabetic nephropathy was associated with  
a non-diabetic renal disease [10]. In other studies evaluating the renal diagnosis in diabetic patients, 
similar results have been reported [11]. In Figure 2, a diabetic patient with hepatitis C virus, and 
nephrotic syndrome showing intraglomerular thrombi associated with crioglobulinemia is shown. 




Figure 2. A patient with nephrotic syndrome, type 2 diabetes and hepatitis C virus associated 
crioglobulinemia. (a) Hematoxilyn-eosin at 100× magnification showing a glomerulus with 
mesangial expansion and another with glomerular thombi; (b) periodic acid Schiff (PAS) 
stain at 400× magnification of the glomerulus showing thrombi; (c) same glomerular section 
at 400× magnification stained with Masson’s trichrome (d) immunohistochemistry showing 
subendothelial C3 deposition in the glomerular lumen. 
The probability to suffer from diabetic nephropathy is high in patients with albuminuria and 
diabetic retinopathy [12]. Absence of diabetic retinopathy even in the presence of macroalbuminuria  
is associated with a high probability of non-diabetic renal disease. Approximately 30% of diabetic 
patients with macroalbuminuria without diabetic retinopathy will show normal histology or renal 
diseases different from diabetic nephropathy [13,14]. Thus, the absence of retinopathy is considered an 
indication for renal biopsy in albuminuric patients. Furthermore, in the Third National Health and 
Nutrition Examination Survey conducted between 1988 and 1994 in adults with T2DM and chronic 
kidney disease (e-GFR lower than 60 mL/min/1.73 m2), one third of patients did not have proteinuria, 
nor diabetic retinopathy, suggesting that this last group of patients might have suffered from a renal 
disease different from classical diabetic nephropathy [15]. Nephroangiosclerosis is a common finding 
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3. Biopsy Indication 
Renal biopsy is indicated in diabetic patients with an atypical presentation of renal disease that could 
be attributed to other renal entities different from diabetic nephropathy. Atypical presentation of renal 
disease in diabetic patients include microalbuminuria without diabetic retinopathy, rapid decline of 
glomerular filtration rate, rapid increase of proteinuria, sudden appearance of the nephrotic syndrome, 
active sediment or the appearance of signs and symptoms of systemic diseases (Table 1) [8,18]. 
Table 1. Atypical presentation of renal disease in diabetic patients. 
Absence of diabetic retinopathy 
Presence of hematuria 
Active urinary sediment (acanthocytes, casts) 
Less than 5 years of evolution of diabetes 
Sudden onset of macroalbuminuria 
Presentation as a nephrotic syndrome 
Rapid decline of renal function 
Acute renal failure 
Clinical suspicion of other nephropathies: vasculitis, glomerulonephritis, amiloidoses 
Markers of systemic diseases: Low complement, ANCA, ANA, dsDNA, cardiolipin antibody, 
ASLO, HIV, M-Spike in serum or urine, cryoglobulins, HBsAg, HCV 
Significant reduction in the GFR (>30%) after ACE inhibitors or angiotensin II receptor blockers 
ANA: antinuclear antibody; dsDNA: double-strand DNA; ASLO: anti-streptolysin O; ANCA: antineutrophil 
cytoplasmic antibody; HBsAg: Hepatitis B surface antigen; HCV: Hepatitis C virus; HIV: human 
immunodeficiency virus. 
Early diagnosis of diseases different from diabetic nephropathy in diabetic patients is fundamental 
to preserve renal function in patients with renal diseases for which the natural history can be modified 
by treatment, especially in primary glomerulonephritis, systemic diseases with renal involvement or 
interstitial nephritis. 
4. Histological Classification of Diabetic Nephropathy 
The International Consensus Document for the Classification of T1DM and T2DM diabetes was 
published in 2010 [9]. The first consensus document for the classification of renal pathology was published 
in 1993 as a proposal for grading renal damage and classifying kidney disease in renal allograft biopsies, 
the so called Banff criteria [19]. A decade later, other international consensus for the classification of 
IgA nephropathy [20], lupus nephritis [21] or focal segmental glomerulosclerosis [22] were published. 
These documents provide a common language for pathologists, nephrologists, surgeons and basic 
scientists, and propose a grading and classification system that can be tested and fine-tuned as new 
knowledge appears. The utility of any classification proposed by consensus depends on its reproducibility 
and the accuracy to predict outcome. The oldest consensus classification, The Banff Classification, has 
been modified several times, but has clearly contributed to speed up knowledge and to improve the 
accuracy of the diagnosis of the different conditions affecting the renal allograft [23,24].  
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The consensus document for the evaluation of diabetic nephropathy establishes a minimum standard 
of quality to evaluate biopsies. Minimum sample size for adequate evaluation is 10 glomeruli and the 
biopsy should be stained with hematoxylin and eosin, periodic acid-Schiff (PAS), Masson trichrome, 
and periodic acid methenamine silver stains. Immunofluorescence requires the use of antibodies 
against IgA, IgG, IgM, C3, C1q, kappa and lambda light chains to rule out other renal diseases.  
A sample must be processed for electron microscopy. 
The severity of lesions is graded according to glomerular involvement in four classes. Class I is 
characterized by normal optimal microscopy and basal glomerular thickening in electron microscopy, 
Class II is characterized by mesangial expansion and it is subdivided in Class IIa and Class IIb 
according to the severity of this lesion. Class III is characterized by the presence of at least one nodular 
lesion (Kimmelstiel-Wilson lesion), provided that there are no more than 50% of sclerosed glomeruli 
and Class IV or advanced diabetic glomerulosclerosis designates biopsies with more than 50% 
glomerulosclerosis when this lesion can be attributed to diabetic nephropathy, that is, the presence of 
Class II or III lesions or a long history of diabetes and diabetic retinopathy. Additionally, the degree of 
interstitial fibrosis, interstitial inflammation, arteriolar hyalinosis and arteriosclerosis are graded. 
However, these findings are not taken into consideration for the final grading of diabetic nephropathy. 
Coexisting disorders have to be also reported. 
Interstitial fibrosis and tubular atrophy (IFTA) is evaluated with a 0–3+ semiquantitative scale as 
the percentage of the total involved area of interstitium and tubules as follows: 0 for absence of 
interstitial fibrosis, 1 for <25%, 2 for 25%–50% and 3 for >50%. In this classification system, the 
threshold between 0 and 1 is different from the Banff criteria that considers <10% of interstitial 
fibrosis as normal. This strict criteria to define a normal tubulo-interstitium will necessarily imply that 
a large proportion of patients have a pathological tubulo-interstitial structure. Interstitial inflammation 
is graded with a 0–2+ semiquantitative scale, 0 for absence of inflammation, 1 for inflammation in 
areas of IFTA and 2 for inflammation in areas with a normal tubulo-interstitial structure. Arterial 
hyalinosis is also classified with a 0–2+ semiquantitative scale as 0 for absent, 1 for at least one area of 
hyaline changes and 2 for more than one area of arteriolar hyalinosis. Finally, it should be reported 
whether the biopsy contains large arteries (yes/no) and arteriosclerosis is graded in the most affected 
artery as 0 for no intimal thickening, 1 when intimal thickening is less than the thickness of the media 
and 2 when intimal thickening is wider than the media. This proposal represents a very important step 
forward, since it can be viewed as a starting point that will allow further understanding of the meaning 
of diabetic lesions as the utility of the classification is evaluated in different clinical settings [25].  
5. Reproducibility of Glomerular Lesions 
The utility of any pathological classification depends on the degree of intra and interobserver 
reproducibility and its capacity for risk stratification. Interobserver reproducibility was evaluated by 
the authors of the consensus document. For this purpose, five observers evaluated 25 biopsies with 
diabetic nephropathy into class I, II, III and IV and the results of this pilot study suggest a satisfactory 
interobserver reproducibility for diabetic glomerular lesions (intraclass correlation coefficient of 0.84) [9]. 
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6. Histological Damage and Outcome 
Different studies have evaluated the utility of The International Consensus Document for the 
Classification T1DM and T2DM to predict risk for renal function deterioration and end stage renal 
disease. In a study including 50 patients with biopsy proven pure diabetic nephropathy, five year renal 
survival rates were associated with diabetic nephropathy class [26]. In another study published the 
same year, including 69 T2DM patients with biopsy proven diabetic nephropathy who did not present 
any class I cases, interstitial fibrosis and tubular atrophy and the severity of interstitial inflammation, 
but not glomerular class, were associated with the main outcome variable defined as initiation of 
dialysis or doubling of serum creatinine at the end of follow up [26]. Despite the small size of both 
studies, they suggest the importance of glomerular and tubulo-interstitial lesions as predictors of 
outcome in diabetic nephropathy.  
Mise et al. [27] retrospectively reviewed 310 biopsies made in patients with diabetes between 1985 
and 2010. In order to evaluate the relationship between biopsy findings and renal outcome, they 
discarded patients with coexistence of other diseases. Finally, they included 205 patients with  
the diagnosis of diabetic nephropathy. In their study, indications for renal biopsy were  
proteinuria >0.5 g/24 h, diabetes without diabetic retinopathy or the presence of hematuria. All 
biopsies were re-evaluated by one observer according to The International Consensus Document 
Guidelines. After correcting for confounding variables (age, gender, e-GFR, type of diabetes, urinary 
protein excretion, systolic blood pressure, body mass index, HbA1c, diabetic retinopathy and presence 
of red blood cells in the urinary sediment) they were able to show that hazard rate (HR) for end stage 
chronic renal failure, defined as the need for dialysis, increased with glomerular class. Class IIa was 
considered the reference value and HR and 95% confidence interval for glomerular classes I, IIb, III 
and IV were 0.21 (95% CI: 0.04–1.25), 2.12 (0.89–5.04), 4.23 (1.80–9.90), and 3.27 (1.32–8.10), 
respectively [27]. Other important findings were that degree of IFTA score, interstitial inflammation 
score, arteriolar hyalinosis and arteriosclerosis score correlated with the main outcome variable. The 
risk for end stage renal disease increased as damage score increases for IFTA, arteriolar hyaline 
changes and intimal thickening. Both inflammation in areas of IFTA (score 1) and in healthy areas 
(score 2) were associated with a significant risk for end stage chronic renal failure suggesting that even 
mild tubulo-interstital inflammation is an important determinant of outcome in diabetic nephropathy. 
This study confirms the utility of the International Consensus Document to classify the risk for 
progression to end stage renal disease. However, in the present study it was not analysed which of the 
evaluated lesions were independent predictors of outcome from glomerular lesions. In another 
retrospective study performed between 2003 and 2011 [28,29] including 396 patients with T2DM with 
biopsy proven diabetic nephropathy, the utility of histology to predict the risk for end-stage renal 
disease or doubling of serum creatinine was evaluated. Renal biopsy was indicated in patients with 
persistent albuminuria, decreased serum creatinine, sudden onset of proteinuria, hematuria or rapid 
progression of renal insufficiency. After five years of follow-up, renal survival rates were 100% in 
class I diabetic nephropathy, 90.1% in class IIa, 75.4% in class IIb, 39.0% in class III and 15.1% in 
class IV. After adjusting for baseline mean arterial blood pressure, proteinuria and e-GFR, glomerular 
lesions remained as an independent risk factor for progression to end stage renal disease and for 
doubling of serum creatinine. IFTA and interstitial inflammation were associated with renal outcome 
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in the univariate analysis, however, only IFTA remained an independent predictor of outcome once the 
statistical model was adjusted for proteinuria, mean arterial blood pressure and e-GFR rate, further 
suggesting that apart from glomerular class, tubulo-interstitial burden of injury is an independent 
predictor of outcome. In this regard, the rate of decline of e-GFR was evaluated in patients with  
T2DM and macroalbuminuria that were biopsied and showed pure diabetic nephropathy according to 
the International Consensus Document. In this study, proteinuria and the degree of IFTA, but not 
glomerular class, were independent predictors of outcome. These data further suggest the importance 
of tubulointerstitial damage as a predictor of outcome [30]. 
Characteristically, biopsies from patients with diabetic nephropathy show a linear immunofluorescent 
staining for immunoglobulin G (IgG) along the glomerular and tubular basement membranes. These 
deposits are not due to immune-complex deposition but to non-specific trapping of immunoglobulins. 
The predictive value of the intensity of IgG immunofluorescence has been evaluated in a study 
including 165 patients with class I to III diabetic nephropathy. Biopsies were classified according to 
immunofluorescence intensity in three categories: 0 for absence of immunofluorescence, 1 for weak 
and 2 for intense staining. The main outcome variable was end stage renal disease. After adjusting for 
clinical and histological variables, the HR for end stage renal disease was 3.01 (1.05–8.68) for patients 
with weak and 4.68 (1.67–13.1) for patients with intense IgG immunofluorescence staining. Despite 
the fact that there was a weak association between glomerular class or glomerular basement membrane 
thickness and immunofluorescence intensity, the predictive value of IgG linear staining was 
independent from histological parameters. This study suggested that the intensity of linear staining is 
related to the severity of basement membrane involvement in diabetes. However, reproducibility of 
immunofluorescence intensity has to be evaluated and the potential utility of this observation should be 
confirmed in an independent cohort [31]. 
7. Renal Biopsy in Clinical Trials Aimed to Modify the Natural History of Diabetic Nephropathy 
In the last years, a large number of new drugs with the potential for slowing renal function decline in 
diabetic patients have been tested in different clinical trials such as Bardoxolone [32], Pyridorin [33], 
Pentoxyfilin [34] and others [35]. 
Clinical trial design in diabetic nephropathy is aimed to show benefit of a new drug on top of renin 
angiotensin system blockade. Inclusion criteria are based on clinical parameters such as renal function 
and degree of proteinuria. Unfortunately, a proportion of patients with non-diabetic nephropathy and 
patients with diabetic nephropathy associated with other renal diseases [10] will be necessarily 
included in trials selecting patients according to clinical criteria. Accordingly, only kidney biopsy at 
entry may allow to exclude patients with renal diseases different from diabetic nephropathy or to 
stratify patients according to histological diagnosis. 
The severity of chronic lesions in diabetic nephropathy roughly correlates with degree of  
proteinuria and renal functional impairment. Inclusion of patients with macroalbuminuria and severe 
renal functional impairment may imply that the severity of lesions may be already beyond the 
threshold of reversibility in a high proportion of patients. Theoretically, the maximal beneficial effect 
of new anti-inflammatory drugs should be obtained in patients with inflammation and relatively 
preserved renal structure. Thus, stratification for the severity of histological damage and severity of 
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renal inflammation may be helpful to better understand which patients will obtain the maximal benefit 
of a new drug. However, the recruitment of a sufficient number of patients for the inclusion of a renal 
biopsy to include and stratify patients in diabetic nephropathy trials may be difficult. 
The Renin-Angiotensin Study (RASS) was a five-year multicenter, randomized, double-blind, 
placebo-controlled trial comparing enalapril and losartan with placebo on early renal structural 
changes from diabetic nephropathy in T1DM patients without hypertension, albumin excretion rate 
above 20 mg/min and a glomerular filtration over 90/mL/min/1.73 m2. The primary study end point 
was a change in the mesangial volume fraction evaluated by means of a renal biopsy performed at 
entry and at five years of follow up. Secondary renal end points included changes in other glomerular, 
vascular, tubular, and interstitial variables and changes in the albumin excretion rate and renal 
function. In this study it was not possible to show any beneficial effect of treatment in comparison to 
placebo in the progression of mesangial volume fraction at this very early stage of disease. However, 
this study raises the question whether renal biopsy may constitute a useful tool to better characterize 
the effect of new drugs to modify the natural history of diabetic nephropathy [36]. In the same cohort 
of patients, macrophage protein 1 (MCP1)/creatinine ratio was measured at entry. This surrogate of 
renal inflammation was associated with an increased interstitial volume fraction at five years in 
females but not in males, pointing out that early inflammation may constitute a risk factor for the 
progression of histological damage in diabetic patients [36]. 
8. Conclusions 
Only a proportion of diabetic patients with renal impairment are biopsied. Thus the preferred term  
for renal disease in diabetics is diabetic kidney disease, while the term diabetic nephropathy is only 
employed in cases with histological confirmation. Available data suggest that approximately one third of 
patients with diabetes that are biopsied show diabetic nephropathy, another third diabetic nephropathy 
with a superimposed non-diabetic disease and the other third a non-diabetic condition. The International 
Consensus Document for the Classification of T1DM and T2DM constitutes an important step forward 
to provide the international community with a common language for the classification of diabetic 
nephropathy. Its clinical utility has already been confirmed in different retrospective studies. New 
treatments for diabetic kidney disease are being tested in different clinical trials. The potential utility of 
renal biopsy to improve the design of clinical trials aimed to modify the natural history of diabetic 
nephropathy remains a matter of discussion.  
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